Vimarsana
Biggest News Aggregation in the World

Developing Topics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Developing Topics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Developing Topics Today - Breaking & Trending Today

Alzheimer's Disease Mechanistic Pathways Discovered through Aitia's Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023 - Vimarsana News

Alzheimer's Disease Mechanistic Pathways Discovered through Aitia's Digital Twins and in silico Experiments in Causal AI to be Presented at AAIC 2023

Published: June 28, 2023

/PRNewswire/ -- Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its...

Source: prnewswire.com
Related Topics:
Noord HollandZena SfeirPrnewswire AitiaGlobal Alzheimer Platform FoundationMedicines PartnershipAlzheimer Association International ConferenceBayesian NetworkAlzheimer Disease Neuroimaging InitiativeDigital TwinsDisease Digital TwinsAssociation International ConferenceGemini Digital TwinsDisease Neuroimaging InitiativeDeveloping TopicsBasic ScienceAccelerating Medicines PartnershipGlobal AlzheimerPlatform Foundation
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023 - Vimarsana News

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023

Published: June 13, 2023

Topline results for ACU193, the first clinical stage amyloid beta oligomer -directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early... | June 13, 2023

Source: marketscreener.com
Related Topics:
Noord HollandNew YorkUnited StatesKimball JohnsonSteven DekoskyEric SiemersDaniel OconnellLawrence HonigDrug AdministrationResearch SavannahAcumen Pharmaceuticals IncResearch SessionAlzheimer Disease At Columbia UniversityAlzheimer Association International ConferenceExchange CommissionMcknight Brain InstituteResearch AtlantaYork State CenterUniversity Of FloridaFeatured Research SessionDeveloping TopicsAssociation International ConferenceDanielo ConnellChief Executive OfficerChief Medical Officer
EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 - Vimarsana News

EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022

Published: July 26, 2022

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimer's...

Source: prnewswire.com
Related Topics:
United StatesSan DiegoHaruo NaitoA Tahami MonfaredLibby HolmanMichael IrizarryUniversity College LondonAlzheimer Association International ConferenceUnited States Veterans Affairs Healthcare SystemAlzheimer NetworkBrain HealthPathophysiological Stages In Dominantly Inherited Alzheimer NetworkPublic Relations DepartmentLtd HeadquartersAsset In DevelopmentEisai Collaboration Research PosterDrug AdministrationEisai IncWashington University School Of MedicineEisai Co LtdPrnewswire Eisai CoAlzheimer Network Trials UnitAssociation International ConferenceBiologics License ApplicationPrescription Drug User Fee Act
Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) - Vimarsana News

Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

Published: July 26, 2022

/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...

Source: prnewswire.com
Related Topics:
United StatesSan DiegoUppsala LanOskar BossonGunilla OsswaldUppsala UniversityVp CommunicationsAlzheimer Association International ConferenceNational Institutes Of HealthNational Institute OnDrug AdministrationAlzheimer Clinical Trial ConsortiumNasdaq StockholmAssociation International ConferenceBiologics License ApplicationPrescription Drug User Fee ActPacific TimePresentation NumberDeveloping TopicsInfusion ReactionsRandomized PhaseOpen Label ExtensionDiverse Participant RecruitmentDisease Prevention TrialAutopsy Findings
BioArctic: Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC) - Vimarsana News

BioArctic: Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

Published: July 26, 2022

STOCKHOLM, July 26, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aß)

Source: finanznachrichten.de
Related Topics:
United StatesSan DiegoUppsala LanOskar BossonGunilla OsswaldUppsala UniversityVp CommunicationsAlzheimer Association International ConferenceNational Institutes Of HealthNational Institute OnDrug AdministrationAlzheimer Clinical Trial ConsortiumNasdaq StockholmAssociation International ConferenceBiologics License ApplicationPrescription Drug User Fee ActPacific TimePresentation NumberDeveloping TopicsInfusion ReactionsRandomized PhaseOpen Label ExtensionDiverse Participant RecruitmentDisease Prevention TrialAutopsy Findings